Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haploidentical IL-15–activated expanded NK cells
- Development stage
- Phase 2
- Lead developer
- Hospital Universitario La Paz
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Haploidentical IL-15–activated expanded NK cells (NKAE cells) are an adoptive cell immunotherapy consisting of natural killer (NK) cells harvested from haploidentical donors. These cells are activated and expanded ex vivo using interleukin-15 (IL-15) and K562-mb15-41BBL feeder cells to enhance their cytotoxic potential and proliferation. The therapy leverages the graft-versus-leukemia effect, where donor NK cells target leukemic cells that lack matching self-MHC ligands (KIR-ligand mismatch). Developed by Antonio Pérez Martínez at Hospital Universitario La Paz, this treatment is primarily investigated for pediatric and young adult patients with relapsed or refractory acute leukemia, often in combination with salvage chemotherapy and post-infusion low-dose IL-2 to support cell persistence.
- Other names
- haploidentical IL-15–activated and expanded peripheral blood NK cellsNKAE cells
02
Targets
MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on haploidentical IL-15–activated expanded NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haploidentical IL-15–activated expanded NK cells.